Friday, Gilead Sciences, Inc. (GILD) announced the successful acquisition of CymaBay Therapeutics, Inc. (CBAY) for around $4.3 billion.
This acquisition involved a tender offer where the majority of CymaBay's shares were bought at $32.50 each.
Following the merger, CymaBay now operates as a fully owned subsidiary of Gilead, and CymaBay's common stock is no longer available for trading on the Nasdaq.
The acquisition is expected to strengthen Gilead's market position by broadening its portfolio with CymaBay's promising investigational lead product candidate, Seladelpar, targeted for treating primary biliary cholangitis and pruritus.
This transaction is projected to impact Gilead's GAAP and non-GAAP 2024 earnings per share by approximately $3.10 - $3.20.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.